Log In Sign up
The largest database of trusted experimental protocols

Alexa fluor 647 conjugated anti cd107a antibody

Manufactured by BioLegend
Visit Supplier

The Alexa-Fluor 647 conjugated anti-CD107a antibody is a fluorescently labeled monoclonal antibody that binds to the CD107a cell surface antigen. CD107a, also known as LAMP-1, is a lysosome-associated membrane protein that is upregulated on the cell surface during degranulation processes. This antibody conjugate can be used to detect and analyze CD107a-expressing cells using flow cytometry or other fluorescence-based techniques.

Automatically generated - may contain errors

Lab products found in correlation

Golgistop, by BD (3 mentions)

Spelling variants of this product

Alexa Fluor 647 (65 citations) Anti-CD107a (26 citations) Anti-CD107a antibody (14 citations) Alexa 647 (11 citations) Anti-CD107a-Alexa Fluor 647 (2 citations) Alexa Fluor 647–conjugated antibody (2 citations)

4 protocols using alexa fluor 647 conjugated anti cd107a antibody

1

Functional Characterization of iPSC-Derived NK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 13

iPSC-derived (iNK) or peripheral blood derived (pbNK) NK cells were either unstimulated (US) or stimulated at a 1:1 ratio with feeder cells for 4 hours. Golgistop (BD Biosciences) and Alexa-Fluor 647 conjugated anti-CD107a antibody (Biolegend) were included during the co-culture period. After four hours, cells were collected and stained for CD45, CD56, and TNF-alpha and analyzed by flow cytometry (FIG. 23A). To assess cytotoxic function iNK or cord blood derived (CBNK) cells were co-cultured with CFSE-labeled target cells at an effector:target ration of 1:1, 3:1 and 10:1 for 90 hours. Quantification of target cells was analyzed every 2 hours with the Incucyte ZOOM cell analysis system (FIG. 23B). It was shown that NK cells derived from iPSC (iNK) using the platform provided herein respond to cellular stimulation to secrete pro-inflammatory cytokines including, but not limited to, TNFα, and have cytotoxic function comparable to peripheral blood and cord blood NK cells.

US10947505B2. Methods and compositions for inducing hematopoietic cell differentiation (2021-03-16). FATE THERAPEUTICS, INC. [US]. Inventors: Bahram Valamehr [US], Raedun Clarke [US], Ryan Bjordahl [US].
+ Open protocol
+ Expand
2

Cytokine Production Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
One-fifth of a whole-lung suspension was incubated at 200 µl per well in a 96-well U-bottom plate in complete RPMI 1640 media. Cells were incubated in the presence of the eBioscence Cell Stimulation Cocktail (plus protein transport inhibitors; diluted 1,000×; Invitrogen) and 2.5 μg ml−1 Alexa Fluor 647-conjugated anti-CD107a antibody (BioLegend). After 4 h, cells were stained for surface markers and intracellular cytokine production and analyzed as described above.
Ng S.S., De Labastida Rivera F., Yan J., Corvino D., Das I., Zhang P., Kuns R., Chauhan S.B., Hou J., Li X.Y., Frame T.C., McEnroe B.A., Moore E., Na J., Engel J.A., Soon M.S., Singh B., Kueh A.J., Herold M.J., de Oca M.M., Singh S.S., Bunn P.T., Aguilera A.R., Casey M., Braun M., Ghazanfari N., Wani S., Wang Y., Amante F.H., Edwards C.L., Haque A., Dougall W.C., Singh O.P., Baxter A.G., Teng M.W., Loukas A., Daly N.L., Cloonan N., Degli-Esposti M.A., Uzonna J., Heath W.R., Bald T., Tey S.K., Nakamura K., Hill G.R., Kumar R., Sundar S., Smyth M.J, & Engwerda C.R. (2020). The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nature immunology, 21(10), 1205-1218.
+ Open protocol
+ Expand
3

Functional Characterization of iPSC-Derived NK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 13

iPSC-derived (iNK) or peripheral blood derived (pbNK) NK cells were either unstimulated (US) or stimulated at a 1:1 ratio with feeder cells for 4 hours. Golgistop (BD Biosciences) and Alexa-Fluor 647 conjugated anti-CD107a antibody (Biolegend) were included during the co-culture period. After four hours, cells were collected and stained for CD45, CD56, and TNF-alpha and analyzed by flow cytometry (FIG. 23A). To assess cytotoxic function iNK or cord blood derived (CBNK) cells were co-cultured with CFSE-labeled target cells at an effector:target ration of 1:1, 3:1 and 10:1 for 90 hours. Quantification of target cells was analyzed every 2 hours with the Incucyte ZOOM cell analysis system (FIG. 23B). It was shown that NK cells derived from iPSC (iNK) using the platform provided herein respond to cellular stimulation to secrete pro-inflammatory cytokines including, but not limited to, TNFα, and have cytotoxic function comparable to peripheral blood and cord blood NK cells.

US11162076B2. Methods and compositions for inducing hematopoietic cell differentiation (2021-11-02). FATE THERAPEUTICS, INC. [US]. Inventors: Bahram Valamehr [US], Raedun Clarke [US], Ryan Bjordahl [US].
+ Open protocol
+ Expand
4

Functional Characterization of iPSC-Derived NK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 13

iPSC-derived (iNK) or peripheral blood derived (pbNK) NK cells were either unstimulated (US) or stimulated at a 1:1 ratio with feeder cells for 4 hours. Golgistop (BD Biosciences) and Alexa-Fluor 647 conjugated anti-CD107a antibody (Biolegend) were included during the co-culture period. After four hours, cells were collected and stained for CD45, CD56, and TNF-alpha and analyzed by flow cytometry (FIG. 23A). To assess cytotoxic function iNK or cord blood derived (CBNK) cells were co-cultured with CFSE-labeled target cells at an effector:target ration of 1:1, 3:1 and 10:1 for 90 hours. Quantification of target cells was analyzed every 2 hours with the Incucyte ZOOM cell analysis system (FIG. 23B). It was shown that NK cells derived from iPSC (iNK) using the platform provided herein respond to cellular stimulation to secrete pro-inflammatory cytokines including, but not limited to, TNFα, and have cytotoxic function comparable to peripheral blood and cord blood NK cells.

US10858628B2. Methods and compositions for inducing hematopoietic cell differentiation (2020-12-08). Fate Therapeutics, Inc. [US]. Inventors: Bahram Valamehr [US], Raedun Clarke [US], Ryan Bjordahl [US].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!